Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
1.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.0K
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine.

The Lancet. Oncology·2026
Same author

Molecular tumor board availability and organization in sarcoma referral centers in Italy: are we on the right track?

Frontiers in oncology·2026
Same author

Editorial: Precision therapeutics in rare cancers: targeting tumor microenvironment and biomarker-driven approaches.

Frontiers in immunology·2026
Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026
Same author

Critical appraisal of patient-reported and clinician-reported outcome measures assessing functional outcomes in lower extremity bone sarcoma patients-a COSMIN-based systematic review.

Journal of patient-reported outcomes·2026
Same author

Complications of PI to PIII hemipelvic resections for intermediate and malignant tumours : a systematic review and meta-analysis.

Bone & joint open·2026

Related Experiment Video

Updated: May 1, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

6.7K

Emerging therapeutic targets for synovial sarcoma.

Emanuela Palmerini1, Anna Paioli, Stefano Ferrari

  • 1Chemotherapy, Musculoskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy.

Expert Review of Anticancer Therapy
|March 26, 2014
PubMed
Summary

Advanced synovial sarcoma treatments are limited. While targeting VEGF showed promise, other pathways like EGFR and mTOR were less effective. Newer strategies focus on CXCR4, immunotherapy, and epigenetic or developmental pathways.

Keywords:
CXCR4HDAC inhibitorsIGFR-1RNY-ESO-1VEGFRmTORnotchsoft tissue sarcomasynovial sarcomatherapeutic targets

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.3K
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.1K

Related Experiment Videos

Last Updated: May 1, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

6.7K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.3K
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

19.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Synovial sarcoma is a rare soft tissue sarcoma with limited effective treatments for advanced stages.
  • Elevated vascular endothelial growth factor (VEGF) expression correlates with higher tumor grade in synovial sarcoma.

Purpose of the Study:

  • To review the efficacy and limitations of current and emerging therapeutic targets for advanced synovial sarcoma.
  • To summarize drug development achievements and challenges against novel targets.

Main Methods:

  • Literature review of preclinical and clinical studies on synovial sarcoma therapeutics.
  • Analysis of drug activity targeting VEGF, EGFR, HER2, IGFR-1R, mTOR, CXCR4, and epigenetic/developmental pathways.

Main Results:

  • VEGF inhibitors (sorafenib, pazopanib, bevacizumab) demonstrated activity in preclinical models and some clinical use.
  • Inhibition of EGFR, HER2, IGFR-1R, and mTOR showed limited meaningful activity in clinical trials.
  • Emerging strategies like CXCR4 inhibition, immunotherapy, HDAC inhibitors, and targeting Notch/Hedgehog pathways are under investigation.

Conclusions:

  • Targeting VEGF offers a validated approach, but broader efficacy requires exploring newer pathways.
  • Significant challenges remain in translating preclinical findings to meaningful clinical activity for advanced synovial sarcoma.
  • Future research should focus on novel targets and combination therapies to improve patient outcomes.